Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett Company has received FDA abbreviated new drug application (ANDA) approval for Hydrochlorothiazide Capsules, 12.5mg.
Subscribe to our email newsletter
Hydrochlorothiazide Capsules, 12.5mg, indicated for the management of hypertension, is therapeutically equivalent to the reference listed drug, Microzide Capsules, 12.5mg, of Watson Pharmaceuticals.
The company is expected to commence shipment of the product shortly.
Lannett president and CEO Arthur Bedrosian said that they have received approvals for and launched record number products thus far in fiscal 2012.
"Hydrochlorothiazide is an important addition to our offering and represents the eighth product approval (seven ANDAs and one NDA) we have received over the last seven months," Bedrosian added.